A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Bausch + Lomb Receives Health Canada Approval for EnVista Envy Trifocal IOL
Author: Jennie Crabbe
The enVista Envy trifocal and toric version (bottom)
Bausch + Lomb announced May 28 that Health Canada had approved the enVista Envy trifocal intraocular lens (IOL).
It’s the first approval for the new lens. The Envy is expected to be available in Canada in mid-June.
Bausch + Lomb said it is seeking regulatory approvals for the Envy in additional markets, including the US and Europe. The enVista Aspire monofocal and toric lenses launched in the US in October 2023.
In a clinical trial in Canada with the Envy, 93 percent of patients reported little to no bothersome dysphotopsias (glare, halo, or starbursts). Ninety-four percent reported little to no difficulty viewing close objects, with excellent spectacle-free distance vision and 4 diopters of continuous visual range.
Bausch + Lomb, headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey, said the Envy features ActivSync distribution to optimize vision in all light levels, and ClearPath technology, which helps reduce light scattering. Low-Cyl toric technology allows the enVista Envy toric lens to simultaneously treat presbyopia and low amounts of astigmatism.